Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron for pulmonary hypertension secondary to heart failure
2016-002949-32Phase 2Terminated
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in pulmonary hypertension (PH) and heart failure (HF) comparing Mirabegron with Placebo (2 arms). Primary endpoint: Change in pulmonary vascular resistance. Started Nov 2016; status: terminated.
02
Drugs
mirabegron
03
Conditions
pulmonary hypertension (PH)heart failure (HF)
Beyond the preview
Go deeper on 2016-002949-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002949-32.